2 ms·
I see is no reason to think the increase in numbers treated would have been so large that payers would have spent more dollars than they did, so its not clear t
by kgwgk 10y ago
I see is no reason to think the increase in numbers treated would have been so large that payers would have spent more dollars than they did, so its not clear that Gilead's revenue (let alone profit) would have been higher.
- refurb 10y agoWe agree to disagree! I think Gilead's pricing scheme left a bad taste in the payer's mouths and probably caused them to be much more restrictive than they otherwise would have. Yes, payers still would have worried about total budget impact, but a lower price means more value. If a payer can spend another $1M and treat another 50 patients (at $20K) vs. 10 patients (at $100K) I get the sense they would have felt it more worthwhile.
- kgwgk 10y agoBut the price is lower now! They could be spending a bit more (or even the same) to treat many more patients than they did in 2015, but instead they choose to spend much less to treat a few more patients. Of course you are free to imagine that it could have happened differently.